Adults 6 to 12, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Axial Length at 36 MonthsPrimary· 36 months
Treatment group comparison of axial length at 36 months, as measured using IOLMaster 700
Group
Value
95% CI
Loading Dose
25.28
25.06 – 25.50
Low Dose
25.25
25.03 – 25.47
Placebo
25.33
25.11 – 25.56
Spherical Equivalent at 36 MonthsPrimary· 36 months
Treatment group comparison of spherical equivalent at 36 months, as measured using cycloplegic autorefraction
Group
Value
95% CI
Loading Dose
-4.45
-4.84 – -4.06
Low Dose
-4.26
-4.65 – -3.87
Placebo
-4.43
-4.83 – -4.03
Adverse EventsSecondary· 36 months
Total individual adverse events per interventional arm
Group
Value
95% CI
Loading Dose
104
Low Dose
22
Placebo
18
Change in Choroidal Thickness From Baseline to 36 MonthsSecondary· 36 months
Treatment group comparison of change in choroidal thickness from baseline to 36 months, as measured using optical coherence tomography (OCT)
Group
Value
95% CI
Loading Dose
2
-11 – 15
Low Dose
7
-3 – 17
Placebo
3
-8 – 14
Adverse events — posted to ClinicalTrials.gov
Time frame: From enrollment to three years.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Myopia (nearsightedness) is increasing in prevalence throughout the world. It is associated with a risk of potentially blinding complications such as retinal detachment and myopic maculopathy. There is a direct association between the degree of myopia and the risk of complications. Myopia develops in childhood and during adolescence. To prevent higher degrees of myopia, we need to halt disease progression in children and teenagers. Low-dose atropine eye drops have been shown to reduce myopia progression by 50% in Asian populations but its effect in non-Asian populations is unknown. The aim of this study is to investigate if low-dose atropine can reduce myopia progression in Danish children and teenagers. The study is an investigator initiated randomized clinical trial conducted as a collaboration between three Danish Eye Departments covering all of Denmark.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Line Kessel
Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03911271.